In November 2025, something truly staggering and utterly groundbreaking happened in the business world. Tesla shareholders ...
24m
Pharvaris (PHVS) Is Up 11.3% After Deucrictibant Shows 92% Drop in HAE Attacks and Reports Q3 Loss
Pharvaris recently presented long-term clinical data at ACAAI 2025, showing deucrictibant achieved a sustained 92.4% reduction in hereditary angioedema attacks over nearly three years, while also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback